ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank25
3Y CAGR-34.7%
Studio
Year-over-Year Change

Cash on hand plus short-term liquid investments

3Y CAGR
-34.7%/yr
Annual compound
Percentile
P25
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$45.54M-38.7%
2024$74.29M-50.6%
2023$150.39M-7.9%
2022$163.37M+338.2%
2021$37.28M-